Timothy Yap

Company: MD Anderson Cancer Center

Job title: Head of Clinical Development and Vice President, Therapeutics Discovery Division, & Professor, Department of Investigational Can

Seminars:

Panel Discussion: What’s Next for DDR Therapeutics? Evaluating Next-Gen PARP Inhibitors, Novel Targets, & the Future of Clinical Validation 4:15 pm

How are biopharma validating novel DDR targets, and what role will next-gen PARP inhibitors play in the evolving landscape of DDR therapeutics? What preclinical frameworks are currently in use for DDR inhibitors, and how can they be enhanced to better predict clinical success and viability? As we look to the future, could expanding data access—such…Read more

day: Day Two

Clinical Advances in the Development of New Generation PARP1- Selective Inhibitors 3:15 pm

Understanding how next-gen PARP1 selective inhibitors maintain efficacy while mitigating toxic side effects Uncovering the ways in which these new molecules diversify the application scenarios of PARP inhibitors in clinic Outlining which novel DDR targets are showing preclinical & clinical potential for the next wave of cancer-targeting drug approvalsRead more

day: Day Two